Certain Balance Sheet Items |
Certain Balance Sheet Items Accounts receivable, net consisted of the following (in thousands): | | | | | | | | | | | | September 30, 2016 | | December 31, 2015 | Accounts receivable from product sales to collaborators | | $ | 10,220 |
| | $ | 4,996 |
| Accounts receivable from other product sales | | 1,912 |
| | 2,442 |
| Accounts receivable from revenues under collaborative agreements | | 5,937 |
| | 25,939 |
| Subtotal | | 18,069 |
| | 33,377 |
| Allowance for distribution fees and discounts | | (390 | ) | | (967 | ) | Total accounts receivable, net | | $ | 17,679 |
| | $ | 32,410 |
|
Inventories consisted of the following (in thousands): | | | | | | | | | | | | September 30, 2016 | | December 31, 2015 | Raw materials | | $ | 1,490 |
| | $ | 677 |
| Work-in-process, net | | 9,708 |
| | 8,481 |
| Finished goods | | 1,654 |
| | 331 |
| Total inventories | | $ | 12,852 |
| | $ | 9,489 |
|
Prepaid expenses and other assets consisted of the following (in thousands): | | | | | | | | | | | | September 30, 2016 | | December 31, 2015 | Prepaid research and development expenses | | $ | 8,801 |
| | $ | 9,225 |
| Other prepaid expenses | | 1,810 |
| | 1,198 |
| Other assets | | 437 |
| | 530 |
| Total prepaid expenses and other assets | | 11,048 |
| | 10,953 |
| Less long-term portion | | 4,986 |
| | 5,574 |
| Total prepaid expenses and other assets, current | | $ | 6,062 |
| | $ | 5,379 |
|
Property and equipment, net consisted of the following (in thousands): | | | | | | | | | | | | September 30, 2016 | | December 31, 2015 | Research equipment | | $ | 10,316 |
| | $ | 9,666 |
| Computer and office equipment | | 3,178 |
| | 2,570 |
| Leasehold improvements | | 2,319 |
| | 2,025 |
| Subtotal | | 15,813 |
| | 14,261 |
| Accumulated depreciation and amortization | | (11,406 | ) | | (10,318 | ) | Property and equipment, net | | $ | 4,407 |
| | $ | 3,943 |
|
Depreciation and amortization expense totaled $0.7 million and $0.4 million for the three months ended September 30, 2016 and 2015, respectively, and $1.8 million and $1.2 million for the nine months ended September 30, 2016 and 2015, respectively. Accrued expenses consisted of the following (in thousands): | | | | | | | | | | | | September 30, 2016 | | December 31, 2015 | Accrued outsourced research and development expenses | | $ | 9,947 |
| | $ | 8,617 |
| Accrued compensation and payroll taxes | | 8,201 |
| | 8,636 |
| Accrued outsourced manufacturing expenses | | 3,706 |
| | 6,205 |
| Other accrued expenses | | 3,890 |
| | 4,118 |
| Total accrued expenses | | 25,744 |
| | 27,576 |
| Less long-term accrued outsourced research and development expenses | | 11 |
| | 784 |
| Total accrued expenses, current | | $ | 25,733 |
| | $ | 26,792 |
|
Long-term accrued outsourced research and development is included in other long-term liabilities in the condensed consolidated balance sheets. Deferred revenue consisted of the following (in thousands): | | | | | | | | | | | | September 30, 2016 | | December 31, 2015 | Collaborative agreements | | | | | License fees and event-based payments: | | | | | Roche | | $ | 36,542 |
| | $ | 39,038 |
| Other | | 8,400 |
| | 9,724 |
| | | 44,942 |
| | 48,762 |
| Reimbursement for research and development services | | 5,799 |
| | 4,461 |
| Total deferred revenue | | 50,741 |
| | 53,223 |
| Less current portion | | 9,892 |
| | 9,304 |
| Deferred revenue, net of current portion | | $ | 40,849 |
| | $ | 43,919 |
|
|